These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25582572)

  • 41. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy.
    Haslbeck KM; Friess U; Schleicher ED; Bierhaus A; Nawroth PP; Kirchner A; Pauli E; Neundörfer B; Heuss D
    Acta Neuropathol; 2005 Sep; 110(3):247-54. PubMed ID: 15986224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Idiopathic inflammatory myopathies from the viewpoint of a neurologist].
    Shimizu J
    Brain Nerve; 2013 Nov; 65(11):1269-74. PubMed ID: 24200604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Autoantibodies in scleroderma and polymyositis: an update.
    McCarty GA
    Semin Dermatol; 1991 Sep; 10(3):206-16. PubMed ID: 1931570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies.
    Dugan EM; Huber AM; Miller FW; Rider LG;
    Dermatol Online J; 2009 Feb; 15(2):2. PubMed ID: 19336019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The anti-synthetase syndrome: muscle disease and multisystem disorder at the same time].
    Hengstman GJ; van Venrooij WJ; van den Hoogen FH; van Engelen BG
    Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1485-9. PubMed ID: 12924076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
    Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
    Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of cytokines and chemokines in idiopathic inflammatory myopathies.
    De Paepe B; Creus KK; De Bleecker JL
    Curr Opin Rheumatol; 2009 Nov; 21(6):610-6. PubMed ID: 19726994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future.
    Dalakas MC
    Neuromuscul Disord; 2006 Apr; 16(4):223-36. PubMed ID: 16542836
    [No Abstract]   [Full Text] [Related]  

  • 49. Inflammatory muscle diseases: a critical review on pathogenesis and therapies.
    Dalakas MC
    Curr Opin Pharmacol; 2010 Jun; 10(3):346-52. PubMed ID: 20409756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Idiopathic inflammatory myopathies: clinical aspects.
    Byrne E; Dennett X
    Baillieres Clin Neurol; 1993 Nov; 2(3):499-526. PubMed ID: 8156141
    [No Abstract]   [Full Text] [Related]  

  • 51. [Antisynthetase syndrome].
    Gran JT
    Tidsskr Nor Laegeforen; 2002 Sep; 122(23):2270-2. PubMed ID: 12448266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical significance of specific autoantibodies in juvenile dermatomyositis.
    Feldman BM; Reichlin M; Laxer RM; Targoff IN; Stein LD; Silverman ED
    J Rheumatol; 1996 Oct; 23(10):1794-7. PubMed ID: 8895161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.
    Mammen AL; Allenbach Y; Stenzel W; Benveniste O;
    Neuromuscul Disord; 2020 Jan; 30(1):70-92. PubMed ID: 31791867
    [No Abstract]   [Full Text] [Related]  

  • 54. [Immunological aspects of polymyositis].
    Takayanagi T; Honda H
    No To Shinkei; 1983 Jun; 35(6):525-33. PubMed ID: 6354219
    [No Abstract]   [Full Text] [Related]  

  • 55. Risk Factors and Cancer Screening in Myositis.
    Moghadam-Kia S; Oddis CV; Ascherman DP; Aggarwal R
    Rheum Dis Clin North Am; 2020 Aug; 46(3):565-576. PubMed ID: 32631604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection.
    Fiorentino D; Casciola-Rosen L
    Arthritis Rheum; 2012 Feb; 64(2):346-9. PubMed ID: 21987176
    [No Abstract]   [Full Text] [Related]  

  • 57. [Physiopathology of polymyositis and dermatomyositis, mechanism of action of intravenous immunoglobulins].
    Mouthon L
    Rev Med Interne; 2004 Dec; 25 Spec No 3():10-2. PubMed ID: 15842099
    [No Abstract]   [Full Text] [Related]  

  • 58. The role of type I interferons and other cytokines in dermatomyositis.
    Arshanapalli A; Shah M; Veerula V; Somani AK
    Cytokine; 2015 Jun; 73(2):319-25. PubMed ID: 25541432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of Ro (SS-A) antibodies in patients with polymyositis.
    Isenberg D; Cambridge J; Maddison PJ
    Arthritis Rheum; 1987 Nov; 30(11):1320. PubMed ID: 3500728
    [No Abstract]   [Full Text] [Related]  

  • 60. Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies.
    Miller FW
    JAMA; 1993 Oct; 270(15):1846-9. PubMed ID: 8411528
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.